COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy.

Coulson, J M; Adams, A; Gray, L A; Evans, A

Coulson, J M; Adams, A; Gray, L A; Evans, A.

Coulson JM; Cardiff University, Cardiff, United Kingdom; All Wales Therapeutics and Toxicology Centre, Cardiff and Vale University Health Board, Llandough, Penlan Road, Cardiff CF64 2XX, United Kingdom. Electronic address: coulsonjm@cardiff.ac.uk.
Adams A; National Antiviral Service, Cardiff and Vale University Health Board, United Kingdom.
Gray LA; All Wales Therapeutics and Toxicology Centre, Cardiff and Vale University Health Board, Llandough, Penlan Road, Cardiff CF64 2XX, United Kingdom.
Evans A; Chief Pharmaceutical Officer for Wales, Health and Social Services Group, Welsh Government, United Kingdom.

J Infect ; 85(4): 436-480, 2022 10.

Article in English | MEDLINE | ID: covidwho-1895208

Subject(s)

COVID-19 Drug Treatment; Ritonavir; Hospitals; Humans; Lopinavir/therapeutic use; Ritonavir/therapeutic use

Keywords

COVID-19; Nirmatrelvir; Paxlovid; Rebound; Recurrence; Ritonavir

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / COVID-19 Drug Treatment Limits: Humans Language: English Journal: J Infect Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google